Last deal

$2M

Amount

Seed

Stage

19.05.2019

Date

3

all rounds

$2.03M

Total amount

date founded

Financing round

General

About Company
Serenity is a therapeutics company focused on cellular stress pathways.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

Serenity has acquired a clinical-stage stress therapeutic called DC-TAB, which has shown promising results in treating multiple sclerosis (MS) patients. Through their internal efforts, they have discovered that this drug could also be beneficial for lupus nephritis, a severe kidney disorder affecting lupus patients. Serenity is now advancing their lead drug, SER-101, for the treatment of lupus nephritis. Additionally, Serenity Bioworks is developing gene therapies to address underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. Their protein-based therapeutics aim to improve patient outcomes and make a significant impact in the field.
Contacts
Similar Companies
1000
Cessation Therapeutics

Cessation Therapeutics

Cessation Therapeutics is a company that develops immunotherapy-based biotech innovation to provide therapeutics for addiction-free living.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

1
Unicycive Therapeutics

Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company that develops treatments for kidney diseases with significant unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Los Altos, CA, USA

total rounds

4

total raised

$86.6M
Nextera AS

Nextera AS

Nextera AS offers a versatile and innovative platform for developing novel therapeutic drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Oslo, Norway

total rounds

1
NFlection Therapeutics

NFlection Therapeutics

NFlection is a biopharmaceutical company that develops novel therapies to address the needs of patients with rare disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Cambridge, MA, USA

total rounds

4

total raised

$41.4M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$2.03M

Money Raised

Their latest funding was raised on 19.05.2019. Their latest round Seed

Date 
Funding Round 
Investors 
Money Raised 
Lead 
19.05.2019
$2M
27.02.2019
2
22.06.2018
2
SOSV

SOSV

SOSV is a global venture capital firm that supports early-stage startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital

Location

Princeton, NJ, USA

count Of Investments

2641

count Of Exists

91
Co-Investors
Investors
3
2

Number of lead investors

3

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Grant
Yes
Convertible Note, Seed
No
Convertible Note, Seed
Velocity

Velocity

Velocity is a corporate investor based in Waterloo, Canada that focuses on funding early-stage tech startups.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Waterloo, ON, Canada

count Of Investments

240

count Of Exists

20
SOSV

SOSV

SOSV is a global venture capital firm that supports early-stage startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital

Location

Princeton, NJ, USA

count Of Investments

2641

count Of Exists

91
Arvind Gupta

Arvind Gupta

Arvind Gupta co-leads Mayfield’s Engineering Biology practice. He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats. As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio. Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium. Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art. Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents. Arvind is married to an Icelander and has two daughters.

current job

SOSV
SOSV

organization founded

1
IndieBio

IndieBio

IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

1

total raised

$25M

count Of Investments

493

count Of Exists

7

People

Employee Profiles
3
Marsela Braunstein

Marsela Braunstein

VP, Translational Research

Spencer Berg

Spencer Berg

Co-Founder & COO

Cody Shirriff

Cody Shirriff

CEO and Co-Founder

Activity

Recent News
0